Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Arqule Inc (ARQL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 488,960
  • Shares Outstanding, K 95,500
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,200 K
  • 36-Month Beta 1.01
  • Price/Sales 118.11
  • Price/Cash Flow N/A
  • Price/Book 46.67

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.45 +12.36%
on 06/21/18
7.21 -30.65%
on 07/09/18
+0.12 (+2.46%)
since 06/19/18
3-Month
2.40 +108.33%
on 05/07/18
7.21 -30.65%
on 07/09/18
+2.05 (+69.49%)
since 04/19/18
52-Week
0.94 +431.91%
on 08/21/17
7.21 -30.65%
on 07/09/18
+3.73 (+293.70%)
since 07/19/17

Most Recent Stories

More News
ArQule to Report Second Quarter 2018 Financial Results on August 1, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the second quarter of 2018 before the market opens on Wednesday, August 1, 2018. The Company will hold...

ARQL : 5.03 (-1.76%)
ArQule Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

ArQule, Inc. (Nasdaq: ARQL) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their...

ARQL : 5.03 (-1.76%)
Free Pre-Market Technical Recap on ArQule and Three Additional Biotech

Stock Research Monitor: ARNA, ARWR, and ATRA

ARQL : 5.03 (-1.76%)
ARNA : 44.29 (+0.93%)
ArQule Announces Pricing of $60.5 Million Public Offering of Common Stock

ArQule, Inc. (Nasdaq: ARQL) today announced the pricing of an underwritten public offering of 11 million shares of its common stock at a price to the public of $5.50 per share. ArQule has...

ARQL : 5.03 (-1.76%)
ArQule Announces Commencement of Proposed Public Offering of Common Stock

ArQule, Inc. (Nasdaq: ARQL) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. In...

ARQL : 5.03 (-1.76%)
ArQule Added to the Russell 2000(R) Index

ArQule, Inc. (Nasdaq: ARQL) today announced that it has been added to the Russell 2000(R) Index, a subset of the Russell 3000(R) Index, effective as of market closing on June 22, 2018,...

ARQL : 5.03 (-1.76%)
ArQule Presents Results from Ongoing Phase 1 Dose Escalation Study of its Reversible BTK Inhibitor, ARQ 531

ArQule, Inc. (Nasdaq:ARQL) today is presenting preliminary results from the Company's Phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and reversible inhibitor of...

ARQL : 5.03 (-1.76%)
ArQule to Present at The JMP Securities Life Sciences Conference on June 21, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at...

ARQL : 5.03 (-1.76%)
Options Traders Expect Huge Moves in ArQule (ARQL) Stock

ArQule (ARQL) needs investors to pay close attention to the stock based on moves in the options market lately.

ARQL : 5.03 (-1.76%)
The Race to Treat Cancer, ArQule Inc. Continues Progress Across All Pipeline Assets

Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on ArQule Inc. (NASDAQ: ARQL), a bio-pharmaceutical...

ARQL : 5.03 (-1.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade ARQL with:

Business Summary

ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage...

See More

Key Turning Points

2nd Resistance Point 5.39
1st Resistance Point 5.26
Last Price 5.03
1st Support Level 5.03
2nd Support Level 4.93

See More

52-Week High 7.21
Last Price 5.03
Fibonacci 61.8% 4.81
Fibonacci 50% 4.07
Fibonacci 38.2% 3.34
52-Week Low 0.94

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar